AstraZeneca spinout Albireo Pharma is moving closer to securing regulatory approval for the company’s treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC).

Cerevel Therapeutics began trading on the Nasdaq.

U.S-based cancer testing startup Grail Inc., a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) with the U.S. Securities and Exchange Commission.

Abbott’s Miles D. White will be stepping down as chief executive officer on March 31, 2020, after a remarkable 21-year tenure, the second longest for a non-founder in today’s S&P 100.

London-based GammaDelta Therapeutics announced the spin-out of Adaptate Biotherapeutics, which will focus on developing an immune response to cancer.

A private British company is developing a vaccine that would be the first in the world to fight all types of flu.

Boehringer Ingelheim tied up a schizophrenia drug under development by Autifony Limited, a 2011 spinout of GSK, in a deal that could be worth up to about $740 million.

EVANSTON, Ill., Sept. 16, 2015 /PRNewswire/ — Aptinyx Inc., a biopharmaceutical company advancing modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging disorders of the brain and nervous system, has launched with the discovery platform and preclinical pipeline spun out of Naurex upon the close of its acquisition by Allergan in August 2015. “As […]